Study offers a differentiated patient-specific solution in minimal residual disease t
Exact Sciences Corp. today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.